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Summary
Background There is no consensus on the treatment of multifocal primary cuta-
neous anaplastic large cell lymphoma (C-ALCL). Radiotherapy (RT) and
methotrexate (MTX) are the current treatment options, but their efficacy is
unknown. Recently, targeted therapies showed promising results in C-ALCL, and
may therefore be an attractive first choice of treatment.
Objectives To assess the efficacy of conventional treatment strategies for patients
with multifocal C-ALCL, and to define which patients may require novel targeted
therapies.
Methods In this multicentre study, treatment was evaluated in patients initially pre-
senting (n = 24) or relapsing with multifocal C-ALCL (n = 17; 23 relapses).
Distinction was made between patients with five or less lesions (n = 36) and
more than five lesions (n = 11).
Results Treatments most commonly used were RT (n = 21), systemic chemother-
apy (n = 9) and low-dose MTX (n = 7) with complete response rates of 100%,
78% and 43%, respectively, and an overall response rate of 100%, 100% and
57%, respectively. Four patients showed complete spontaneous regression. In
total, 16 of 24 patients (67%) first presenting with multifocal C-ALCL relapsed,
including all five patients initially treated with CHOP (cyclophosphamide,
hydroxydaunorubicin, oncovin and prednisone). Compared with patients present-
ing with two to five skin lesions, patients presenting with more than five lesions
had a higher chance of developing extracutaneous relapse (56% vs. 20%) and
more often died of lymphoma (44% vs. 7%).
Conclusions Patients with five or less lesions should be treated with low-dose RT
(2 9 4 Gy). Maintenance low-dose MTX (20 mg weekly) is a suitable option in
patients with more than five lesions. Targeted therapies may be considered in rare
patients who are refractory to MTX or patients developing extracutaneous disease.
What’s already known about this topic?
• There is no consensus on the treatment of multifocal primary cutaneous anaplastic
large cell lymphoma (C-ALCL).
• New targeted therapies are evaluated without knowledge of the efficacy of conven-
tional therapies.
© 2018 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
724 British Journal of Dermatology (2018) 179, pp724–731
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
What does this study add?
• This study evaluated the efficacy of conventional therapies for multifocal C-ALCL.
• Radiotherapy and low-dose methotrexate are suitable options in patients with five
or less and more than five lesions, respectively.
• Targeted therapies may be considered in rare patients who are refractory to
methotrexate or developing extracutaneous disease.
Primary cutaneous anaplastic large cell lymphoma (C-ALCL)
is an indolent T-cell lymphoma, comprising about 10% of
all cutaneous T-cell lymphomas.1 Most patients present with
solitary or localized nodules or tumours, which often show
ulceration.2 Approximately 15–20% of the patients with C-
ALCL present with multifocal lesions involving multiple
anatomical areas.2–4 Although there is broad consensus that
radiotherapy is the first choice of treatment in solitary or
localized C-ALCL, there is uncertainty about the optimal
treatment of patients with multifocal C-ALCL.1,2,5–8 Initial
studies suggested that these patients should be treated with
doxorubicin-based chemotherapy.9 However, in more recent
studies of our group, it was found that all patients treated
with multiagent chemotherapy developed relapses during fol-
low-up.2 It was therefore concluded that multiagent
chemotherapy should no longer be considered as first-choice
therapy in patients with multifocal C-ALCL, but should be
reserved for patients developing extracutaneous disease.2 In
that study, in which 17 of 79 patients presented with multi-
focal C-ALCL, we suggested that patients with multifocal C-
ALCL can best be treated with radiotherapy in the case of
few lesions or with low-dose methotrexate (MTX) in the
case of more widespread disease.2 These guidelines were
adopted by the International Society for Cutaneous Lym-
phomas and by the European Society for Medical Oncology,
but have not been substantiated by further publications.5,10
In particular, studies on MTX are scarce and restricted to a
few case reports.11–14
Recent studies reported high response rates to brentuximab
vedotin (BV), an antibody–drug conjugate composed of an anti-
CD30 monoclonal antibody conjugated to the microtubule-dis-
rupting agent monomethyl auristatin E, in the treatment of pri-
mary cutaneous CD30-positive lymphoproliferations.7,15–20
Consequently, National Comprehensive Cancer Network guide-
lines have already incorporated BV as a primary treatment
option in multifocal C-ALCL.21 However, to decide which treat-
ment should be selected, it is essential that more data on the
results of treatments currently used for multifocal C-ALCL be
made available. In the present study we therefore evaluated the
treatment results of 35 patients initially presenting with multifo-
cal C-ALCL or relapsing with multifocal skin lesions. The main
goal of this study was to define which patients with multifocal
C-ALCL should be treated with conventional therapies, and
which patients may require novel targeted therapies. In
addition, long-term follow-up data of 24 patients with multifo-
cal C-ALCL at first presentation are presented.
Patients and methods
Patient selection
From 283 patients with C-ALCL, who had been included in
the Dutch registry for cutaneous lymphomas between October
1985 and December 2016, 28 patients (10%) presented with
skin lesions on multiple anatomical regions. After exclusion of
patients with an ALK-positive C-ALCL (n = 1), insufficient fol-
low-up data (n = 1), underlying immunodeficiency (n = 1) or
patients who had died before initial therapy (n = 1), 24
patients with multifocal C-ALCL at first presentation were
selected for the present study. Furthermore, we selected 17
patients who developed multifocal skin relapses (n = 23) dur-
ing follow-up. This group included six of the initial 24
patients, who developed multifocal relapses 4–78 months
(median, 20 months) after initial treatment, and 11 patients,
who relapsed with multifocal skin lesions 3–96 months (me-
dian, 13 months) after initial treatment with excision or
radiotherapy for a solitary lesion.
A total of 23 histologically confirmed skin relapses without
concurrent extracutaneous localizations were included: 14 of 17
patients experienced one multifocal skin relapse and three
patients had each of two, three or four multifocal skin relapses,
respectively. All multifocal relapses occurred at different local-
izations and at least 3 months after preceding lesions, and thus
were not considered as continuations of previous treatment. In
all cases, the diagnosis was made by an expert panel of derma-
tologists and pathologists of the Dutch Cutaneous Lymphoma
Group and all cases met the clinicopathologic criteria of the
World Health Organization–European Organization for
Research and Treatment of Cancer classification.1
Extracutaneous disease was excluded by routine staging pro-
cedures, including complete blood count, biochemical analy-
sis, computed tomography scan of chest, abdomen and neck
and, if applicable, bone marrow examination. None of the
patients showed waxing and waning of the lesions, character-
istic of lymphomatoid papulosis (LyP). Follow-up data, which
are collected yearly by the Dutch Cutaneous Lymphoma
group, were retrieved from the Dutch registry of cutaneous
lymphomas or, if incomplete, from referring medical centres.
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The following characteristics were recorded: age at time of
diagnosis, sex, type and number of skin lesions, spontaneous
remission, type and result of treatment, occurrence and site of
relapse and status at the time of last follow-up. Using the
TNM classification for primary cutaneous lymphomas other
than mycosis fungoides and Sezary syndrome, distinction was
made between stage T3a (multiple lesions involving two non-
contiguous body regions) and T3b (multiple lesions involving
three or more body regions).22 For the purpose of this study,
the number of skin lesions was scored as 2, 3–5, 6–10 and
> 10. However, few clustered lesions fitting within a radiation
field with a diameter of 15 cm were not counted separately,
but considered as one lesion. Since patients with up to five
lesions are still considered eligible for radiotherapy, distinction
was made between multifocal C-ALCL with two to five lesions
and multifocal C-ALCL with more than five lesions.
Response assessments were performed 4–6 weeks after
treatment and follow-up visits were scheduled every 3–
6 months, and more frequently during chemotherapy. Com-
plete response (CR) was defined as complete disappearance of
the skin lesions, partial response (PR) as > 50% regression of
the skin lesions, stable disease was defined as < 50% regres-
sion or < 25% increase of the skin lesions and progressive dis-
ease as > 25% increase in skin lesions. CR and PR were taken
together as overall response. This retrospective study was
evaluated by the ethics committee of the Leiden University
Medical Center and provided with a waiver of consent.
Results
Multifocal cutaneous anaplastic large cell lymphoma at
first presentation (n = 24)
Clinical characteristics
Main clinical characteristics of the 24 patients initially present-
ing with multifocal lesions are summarized in Table 1, and pre-
sented in more detail in Table 2. The study group included 19
men and five women with a median age at diagnosis of
56 years (range, 25–88 years). Fifteen of 24 patients had two
to five lesions and nine patients had more than five lesions at
first presentation. Most patients presented with mainly tumor-
ous lesions (n = 18), three patients with plaques and three
patients had papules without waxing and waning typical of LyP.
Skin lesions were located on the trunk (n = 13), arms (n = 17),
legs (n = 15) and on the head/neck to a lesser extend (n = 6).
Partial or even complete spontaneous regression of all skin
lesions was observed in seven and four patients, respectively.
Treatment response
The type and result of initial treatment are presented in
Tables 2 and 3. Initial therapy consisted of radiotherapy in
seven patients, low-dose MTX in four patients and multiagent
chemotherapy with CHOP (cyclophosphamide, hydroxy-
daunorubicin, oncovin and prednisone) in five patients. All
seven patients treated with radiotherapy (median dose: 25 Gy;
range: 8–40 Gy) had presented with less than five lesions and
CR was observed in all of them. Also, all five patients treated
with CHOP courses reached CR. Treatment with low-dose
MTX (median dose: 2375 mg, range: 10–35 mg) resulted in
CR in one of four patients and a PR in another (Fig. 1).
Remaining patients were variously treated with psoralen–ultra-
violet A (PUVA) (n = 2; 1 CR, 1 PR), etoposide (n = 1; CR)
or excision (n = 1; CR) (Table 2). Four patients, including
two patients presenting with more than five lesions, showed
complete remission of all lesions without any treatment 4, 4,
8 and 20 weeks after initial presentation.
Table 1 Clinical characteristics of patients initially presenting with
multifocal cutaneous anaplastic large cell lymphoma (n = 24)
Characteristic Variable
Sex, men : women 19 : 5
Age, years
Median 56
Range 25–88
Spontaneous remission
Partial 7 (29)
Complete 4 (17)
Number of skin lesions
2 6
3–5 9
6–10 4
> 10 5
T-scorea
3a 12
3b 12
Initial therapy
CHOP (like) 5
Radiotherapy (+ excision) 7
Methotrexate 4
Other 4
None (spontaneous remission) 4
Results of initial therapy
Complete response 20 (83)
Partial response 2 (8)
No response/progression 2 (8)
Relapse
No relapse 8 (33)
Skin only 8 (33)
Skin and extracutaneous disease 8 (33)
Current status
Alive without disease 12 (50)
Alive with disease 4 (17)
Died of lymphoma 5 (21)
Died of other cause 3 (12)
Median follow-up, months (range) 44 (11–283)
5-year disease-specific survival, % 78
5-year overall survival, % 66
Values are n (%) unless otherwise indicated. CHOP, cyclophos-
phamide, hydroxydaunorubicin, oncovin and prednisone. aT-score
from the TNM classification for primary cutaneous lymphomas
other than mycosis fungoides and Sezary syndrome;22 T3, general-
ized skin lesions involving 2 (T3a) or ≥ 3 (T3b) noncontiguous
body regions.
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Table 2 Clinical characteristics initial multifocal cutaneous anaplastic large cell lymphoma (n = 24)
Patient Sex
Age,
years Clinical presentationa
Spontaneous
regression
Received
therapy
Result
therapy
Relapse/progression
(months)
Follow-
up
(months)
1 M 55 > 10 partial ulcerating tumours and
papules/plaques on the extremities
and lower back (T3b)
Partial CHOP CR Skin (10), lymph node
(38), pulmonary (40)
D+ (42)
2 M 56 Tumour left axilla, right forearm and
elbow (T3a)
No CHOP CR Skin (19) Ao
(118)
3 M 38 4 papules on left knee, left side,
bilateral glute (T3b)
Partial PUVA PR Skin (13) and lymph
node (15)
Ao
(168)
4 M 54 8 ulcerating tumours on the back and
upper arms (T3b)
No CHOP+RT CR Skin (12), skin (60),
lymph node (115),
pulmonary (120)
D+
(132)
5 M 31 Ulcerating tumour right hand, right
upper arm, left foot (T3b)
Complete Expectative CR No Ao (72)
6 M 88 30 partial ulcerating papules and
tumours trunk and arms (T3b)
No Etoposide CR No Do (19)
7 F 40 Tumour on left shoulder, two plaques
back and left arm (T3a)
No CHOP CR Skin (13), lymph node
(133)
Ao
(283)
8 M 46 Ulcerating tumour right wrist, papule
right knee and groin (T3a)
No RT CR Skin (13) Ao (61)
9 F 85 Tumour left upper arm and tumour
right gluteus (T3a)
No RT CR No Ao (21)
10 M 57 Plaque head and papules right axilla
(T3a)
No CHOP CR Skin (20) Ao (46)
11 M 25 Tumour left eye, abdominal, back and
left side (T3b)
Partial MTX
25 mg
CR Skin (18) A+ (19)
12 M 40 10 papules and tumours on trunk,
arms and legs (T3b)
Complete Expectative CR No Ao
(164)
13 M 44 8 partial ulcerating tumours left hand,
left forearm, left axilla and left
forehead (T3b)
Complete Expectative CR Skin (18), skin (78)
lymph node (78)
A+
(205)
14 F 86 Tumour left elbow and right upper leg
(T3a)
Partial RT leg CR Skin (19) Do (21)
15 F 85 Disseminated plaques on trunk, arms
and legs (T3b)
No PUVA CR No Do (25)
16 M 65 Ulcerating tumours trunk, arms and
legs (T3b)
Partial MTX
225 mg
SD Skin and lymph node
(8)
D+ (24)
17 M 63 2 ulcerating tumours parietal right and
right groin (T3a)
No Excision CR Skin (4), skin and
lymph node (31)
D+ (32)
18 M 45 6 partial ulcerating papules, lower leg,
lower back (T3b)
No MTX 75–
35 mg
PD Skin (5), pulmonary and
renal (13)
D+ (20)
19 M 80 3 tumours neck, occipital, left arm
(T3a)
Partial RT and
excision
CR Skin (10) Ao (27)
20 M 50 3 plaques right knee, upper right leg,
upper right arm (T3a)
Complete Expectative CR No Ao (55)
21 M 79 6 localized papules right knee and
papule abdominal (T3a)
No RT and
excision
CR No Ao (50)
22 M 59 Tumour right knee and papule right
wrist (T3a)
No RT CR Skin (12) Ao (48)
23 F 61 Tumour and plaque upper left leg,
papule on left shoulder and upper
right arm (T3a)
No RT CR Skin (5) A+ (40)
24 M 27 > 30 partial ulcerating tumours
disseminated over body (T3b)
Partial MTX
10 mg
PR – A+ (11)
M, male; F, female; CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone; RT, local radiotherapy; MTX, methotrexate;
PUVA, psoralen–ultraviolet A; CR, complete response; PR: partial response; Ao, alive without lymphoma; A+, alive with lymphoma; Do, died
of unrelated disease; D+, died of lymphoma; SD, stable disease; PD, progressive disease. aT-score from the TNM classification for primary
cutaneous lymphomas other than mycosis fungoides and Sezary syndrome;22 T3, generalized skin lesions involving 2 (T3a) or ≥ 3 (T3b)
noncontiguous body regions.
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Follow-up
During follow-up, 16 of 24 patients (67%) developed one or
multiple cutaneous relapses, including all five patients initially
treated with CHOP (Table 2). Eight of these 16 patients devel-
oped extracutaneous disease as well. Median time to relapse was
125 months (range, 4–20 months). Compared with patients
presenting with two to five lesions, patients presenting with
more than five lesions more often developed extracutaneous dis-
ease (3/15 patients; 20% vs. 5/9 patients; 56%) and more often
died of lymphoma (1/15 patients; 7% vs. 4/9 patients; 44%).
Interestingly, three of four patients with complete spontaneous
resolution of all skin lesions did not show relapse 32, 53 and
72 months after diagnosis. After a median follow-up of
44 months, 12 patients were alive without disease, four patients
were alive with disease, five patients died of their lymphoma
and three patients died of another cause. Five-year disease-speci-
fic survival (DSS) was 78%, five-year overall survival (OS) was
66%, and median time to progression (development of extracu-
taneous disease) was 345 months (range 8–133 months).
Multifocal relapse (n = 23)
Results of treatment of 23 multifocal skin relapses in 17
patients with C-ALCL were evaluated. In total, 21 of 23
relapses presented in individuals with five or less lesions.
Radiotherapy (median dose: 20 Gy; range: 8–40 Gy) was
used in 14 of 21 cases relapsing with two to five skin lesions
and resulted in CR in all of them. Three patients were treated
with MTX, resulting in a CR in two patients and stable disease
in one patient. Treatment with CHOP showed two CRs and
two PRs. Treatment of the remaining two patients, both pre-
senting with three distant skin lesions, with acitretin or
intralesional steroids resulted in PR and CR, respectively.
Cumulative results of treatment
Cumulative results of treatment of 47 clinical presentations of
multifocal C-ALCL, including 24 at first presentation and 23
during follow-up are presented in Table 4. Multifocal C-ALCL
concerned two to five skin lesions in 36 patients and more
than five lesions in 11 patients. Local radiotherapy, in some
cases combined with excision, was used in 21 of 36 patients
presenting with two to five lesions and resulted in CR in all of
them. Methotrexate was administered to seven individuals,
including four with five or less lesions, and showed a CR rate
and an overall response rate (ORR) of 43% and 57%, respec-
tively. Seven patients, including four with more than five
lesions, received maintenance treatment with MTX for
6–23 months (median, 105 months).
The results showed a CR in three of seven patients and a PR
in one of seven patients (ORR 57%), whereas the effect was
insufficient in the other three patients. From the four respon-
ders, two patients, including the patient with PR still receive
low-dose MTX, one patient developed a skin relapse
18 months after cessation of MTX treatment, which was suc-
cessfully treated with radiotherapy, and one patient has been
in complete remission for 24 months after cessation of MTX
treatment. CHOP was used in nine patients and resulted in a
CR in seven of nine patients (78%) and PR in the other two
patients. Remaining patients were treated with PUVA (n = 2;
1 CR and 1 PR), etoposide (n = 1; CR), acitretin (n = 1; PR),
excision (n = 1; CR), intralesional corticosteroids (n = 1; CR)
or did not receive treatment because of spontaneous remission
of all skin lesions (n = 4).
Discussion
The current multicentre study describes the largest series of
patients with multifocal C-ALCL published thus far. Although
the main focus of this study was to establish the efficacy of
recommended therapies for patients with C-ALCL with multi-
focal skin lesions and to define which patients are eligible for
novel targeted therapies, we will first summarize other impor-
tant findings of this study, which are relevant to the choice of
treatment. First of all, our study suggests that multifocal C-
ALC is much more uncommon than reported previously. Pre-
vious studies reported that approximately 15–20% of the
patients with C-ALCL have multifocal lesions.2–4 However,
from the 283 patients with C-ALCL that had been included in
the Dutch Cutaneous Lymphoma Registry between 1985 and
2017, only 28 had multifocal skin lesions at first presentation
(10%), and only nine of them had first presented with more
than five affected skin sites (3%). Consistent with previous
Table 3 Treatment results in multifocal cutaneous anaplastic large cell lymphoma at first diagnosis (n = 24)
Therapy Patients Complete response Relapse only skin Extracutaneous relapse Total relapse
CHOP 5 5/5 (100) 2/5 3/5 5/5 (100)
Methotrexate 4 1/4 (25) 1/4 2/4 3/4 (75)
RT (+ excision) 7 7/7 (100) 5/7 0/7 5/7 (71)
Spontaneous remission 4 4/4 (100) 0/4 1/4 1/4 (25)
PUVA 2 1/2 (50) 0/2 1/2 1/2 (50)
Etoposide 1 1/1 (100) 0/1 0/1 0/1 (0)
Excision 1 1/1 (100) 0/1 1/1 1/1 (100)
Total 24 20/24 (83) 8/24 (33) 8/24 (33) 16/24 (67)
Values are n/N (%). CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone; RT, local radiotherapy; PUVA, psoralen–ultra-
violet A.
© 2018 The Authors. British Journal of Dermatology
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studies, patients with multifocal C-ALCL had a much higher
relapse rate (67%), more often developed extracutaneous
disease (33%) and had a lower 5-year DSS (78%) and 5-year
OS (66%) compared with patients with solitary or localized
C-ALCL (40% relapse rate: 10% extracutaneous relapse rate; 5-
year DSS 95% and 5-year OS 85%).2,4,23,24 The high relapse
rate was irrespective of administered therapy. Interestingly,
compared with patients presenting with two to five skin
lesions, patients presenting with more than five lesions had a
higher chance of developing extracutaneous relapse (56% vs.
20%) and more often died of lymphoma (44% vs. 7%).
Current guidelines suggest that patients with C-ALCL pre-
senting with multifocal skin lesions can best be treated with
radiotherapy in the case of few lesions or with low-dose MTX
in the case of more widespread disease.2,5,10 To establish the
efficacy of these therapies, we evaluated the results of initial
treatment in 24 patients with multifocal C-ALCL at first pre-
sentation and 23 multifocal skin relapses. Taken together, 36
of 47 patients had two to five lesions and 11 more than five
lesions. Therapies most commonly applied were radiotherapy
(n = 21), CHOP (n = 9) and low-dose MTX (n = 7), whereas
four cases had not received any treatment because of sponta-
neous resolution of all skin lesions. Other patients were trea-
ted with PUVA in two cases, and etoposide, acitretin,
intralesional corticosteroids and excision, each in one case.
Radiotherapy was successfully used in 21 patients with two
to five skin lesions and resulted in a CR in all of them. Recent
studies of our group suggest that for patients with multifocal
or relapsing skin lesions a radiation dose of 8 Gy (2 9 4 Gy)
suffices.25 Combination therapy with CHOP resulted in a CR
in seven of nine patients and in a PR in the other two. As
reported previously, all patients developed cutaneous and/or
Fig 1. Patient with multifocal cutaneous anaplastic large cell lymphoma before (left) and 5 months after (right) treatment with methotrexate
10 mg showing partial response (patient 24, Table 2).
Table 4 Treatment results in multifocal cutaneous anaplastic large cell lymphoma (n = 47)
Therapy Patients > 5 lesions Complete response Overall response rate
CHOP 9 3/9 (33) 7/9 (78) 9/9 (100)
Methotrexate 7 4/7 (57) 3/7 (43) 4/7 (57)
RT (+ excision) 21 0/21 (0) 21/21 (100) 21/21 (100)
Spontaneous remission 4 2/4 (50) 4/4 (100) 4/4 (100)
Other 6 2/6 (33) 4/6 (66) 6/6 (100)
Total 47 11/47 (23) 39/47 (83) 44/47 (94)
Values are n/N (%). CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone; RT, local radiotherapy. Other: psoralen–ultra-
violet A (n = 2), etoposide (n = 1), acitretin (n = 1), steroids (n = 1) and excision (n = 1).
© 2018 The Authors. British Journal of Dermatology
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extracutaneous relapses during follow-up.2 Following our
publication in 2000, CHOP was therefore no longer used for
patients with only multifocal skin lesions and has been largely
replaced by low-dose MTX.
Low-dose MTX is effective in patients with LyP with
response rates up to 93%,26,27 and has been proposed as first-
line therapy for multifocal C-ALCL.2,5,10 However, evidence
for this recommendation is scarce. Vonderheid et al. suggested
that low-dose MTX is an effective and well-tolerated treatment
in patients with primary cutaneous CD30-positive lymphopro-
liferative disorders, but only four of the 45 patients included
in that study had typical (multifocal) C-ALCL.11 In addition,
few case reports described CRs or PRs in patients with multi-
focal C-ALCL.12–14,28–30 In the present study seven patients
were treated with low-dose MTX, including four with more
than five lesions. Four patients obtained a CR or PR (ORR
57%) during maintenance therapy with MTX, whereas three
patients experienced insufficient effect. These data suggest that
low-dose MTX may be effective in multifocal C-ALCL,
although the response rate is lower than reported in LyP.26,27
Moreover, relapses are common and continued or repeated
maintenance treatment is often required. Apart from MTX,
anecdotal case reports and small series suggest that etoposide,
vinblastine and retinoids (bexarotene, acitretin and isotreti-
noin) alone, or in combination with interferon alpha may
represent alternative effective and well-tolerated options for
refractory multifocal C-ALCL.7,8,31–35
Recent studies report high response rates of BV in patients
with primary cutaneous CD30-positive lymphoproliferations,
including patients with relapsed and extracutaneous (multifo-
cal) C-ALCL.15,16,18–20 A recent phase III trial compared the
efficacy of BV in 16 patients with C-ALCL, including 12
patients with multifocal skin lesions and seven patients with
extracutaneous disease, to MTX or bexarotene in 15 patients
with C-ALCL including six with multifocal skin lesions and
four with extracutaneous disease.20 Patients treated with BV
showed an ORR lasting at least 4 months and an CR rate of
75% and 31%, respectively, compared with 20% and 7%,
respectively, in the control group. Grade 3–4 adverse events
were reported in 41% and peripheral neuropathy in 67% of
the patients in the BV group. Because of the favourable results,
BV was included in the National Comprehensive Cancer Net-
work guidelines as a primary treatment option in multifocal
C-ALCL.21
In conclusion, the results of our study suggest that multifo-
cal C-ALCL is much more uncommon than reported previ-
ously, and most of these patients present with few scattered
skin lesions. In patients showing signs of spontaneous remis-
sion, an expectant policy should be considered, at least for a
short period of 4–6 weeks. In case of complete spontaneous
remission, no further treatment is required. For patients pre-
senting with, arbitrarily, up to five skin lesions, low-dose
radiotherapy (2 9 4 Gy) is the preferred treatment with CR in
virtually all cases. For rare patients presenting with extensive
skin lesions, radiotherapy is less attractive and systemic therapy
is indicated. Maintenance treatment with low-dose MTX (10–
25 mg weekly) may achieve objective response rates of 57%
and is still advised as the first option. BV may be considered in
rare patients with more than five affected skin sites refractory
to MTX or patients with extracutaneous disease (Fig. 2). How-
ever, BV is expensive, long-term effects are still unknown and
the cumulative neuropathy is a matter of concern.20 It would
be interesting to find out if dose reduction and prolonged
treatment intervals can overcome these issues.36 Multiagent
chemotherapy is only indicated in patients with extracutaneous
disease, who do not respond to less aggressive therapies.
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